$INCY

Stein Steven H sold $215K of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 1,877 shares of INCYTE CORP (INCY) at $114.73 ($0.22M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 20, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosed sale amount and execution details are new, but the presence of a pre-arranged 10b5-1 plan makes it less likely to be a fresh negative fundamental signal.

02

Market read

Traders may treat this as routine insider activity with limited immediate impact on valuation, but it can be used to monitor insider behavior trends.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-20, covering a sale executed 2026-07-16.

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by the CMO and Head of Late-Stage Development.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows CMO Steven H Stein sold 1,877 shares on 2026-07-16 for about $215,348 under a 10b5-1 plan.

Expected impact

Minimal, unless follow-on filings show unusual selling outside 10b5-1 or a pattern change.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies the sale was under a pre-arranged 10b5-1 plan, which typically reduces interpretive signal.

Market effects

No direct sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management de-risking ahead of catalysts, so traders may watch for clustering of similar sales.

Key entities

  • INCY

    Incyte Corporation, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

$INCYHighAI 8/10

Incyte Stock: Is Wall Street Bullish or Bearish?

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.